Wood R - Search Results

1

Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.

O'Connor J, Vjecha MJ, Phillips AN, Angus B, Cooper D, Grinsztejn B, Lopardo G, Das S, Wood R, Wilkin A, Klinker H, Kantipong P, Klingman KL, Jilich D, Herieka E, Denning E, Abubakar I, Gordin F, Lundgren JD; INSIGHT START study group. O'Connor J, et al. Among authors: wood r. Lancet HIV. 2017 Mar;4(3):e105-e112. doi: 10.1016/S2352-3018(16)30216-8. Epub 2017 Jan 5. Lancet HIV. 2017. PMID: 28063815 Free PMC article. Clinical Trial.

2

Pulmonary tuberculosis in HIV infection: radiographic appearance is related to CD4+ T-lymphocyte count.

Post FA, Wood R, Pillay GP. Post FA, et al. Among authors: wood r. Tuber Lung Dis. 1995 Dec;76(6):518-21. doi: 10.1016/0962-8479(95)90527-8. Tuber Lung Dis. 1995. PMID: 8593372

3

Antiretroviral therapy in South Africa--can we do it?

Bekker LG, Wood R. Bekker LG, et al. Among authors: wood r. S Afr Med J. 2002 Mar;92(3):191-3. S Afr Med J. 2002. PMID: 12040936 Review. No abstract available.

4

Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study.

Badri M, Wilson D, Wood R. Badri M, et al. Among authors: wood r. Lancet. 2002 Jun 15;359(9323):2059-64. doi: 10.1016/S0140-6736(02)08904-3. Lancet. 2002. PMID: 12086758

5

Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings.

Badri M, Wood R. Badri M, et al. Among authors: wood r. AIDS. 2003 Mar 7;17(4):541-5. doi: 10.1097/00002030-200303070-00009. AIDS. 2003. PMID: 12598774

6

Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort.

Lawn SD, Badri M, Wood R. Lawn SD, et al. Among authors: wood r. AIDS. 2005 Dec 2;19(18):2109-16. doi: 10.1097/01.aids.0000194808.20035.c1. AIDS. 2005. PMID: 16284460

7

When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.

Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, Orrell C, Wood R. Badri M, et al. Among authors: wood r. Antivir Ther. 2006;11(1):63-72. Antivir Ther. 2006. PMID: 16518961

8

CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa.

Lawn SD, Myer L, Bekker LG, Wood R. Lawn SD, et al. Among authors: wood r. BMC Infect Dis. 2006 Mar 21;6:59. doi: 10.1186/1471-2334-6-59. BMC Infect Dis. 2006. PMID: 16551345 Free PMC article.

9

Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control.

Lawn SD, Myer L, Bekker LG, Wood R. Lawn SD, et al. Among authors: wood r. AIDS. 2006 Aug 1;20(12):1605-12. doi: 10.1097/01.aids.0000238406.93249.cd. AIDS. 2006. PMID: 16868441

10

Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study.

Badri M, Lawn SD, Wood R. Badri M, et al. Among authors: wood r. Lancet. 2006 Oct 7;368(9543):1254-9. doi: 10.1016/S0140-6736(06)69117-4. Lancet. 2006. PMID: 17027731

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,394 results

Search Page